NovoMedix’s clinical candidates have novel biological response profiles
NovoMedix discovers and develops proprietary small molecules that modulate key regulatory pathways
including Interleukin-11 (IL-11), mTORC1, p-AKT, p-Stat3, p-Erk, 𝛼-SMA and AMPK, which drive cancer,
fibrosis, and/or heart disease. While all are important, the main focus of NovoMedix is the inhibition
of IL-11, an emerging, compelling therapeutic target in both oncology and fibrosis. IL-11 is a
tumor-promoting cytokine that endows “hallmarks of cancer” activities such as survival, proliferation,
invasion, angiogenesis as well as metastasis, and also is increasingly recognized as a key determinant
of lung/liver fibrosis, inflammation, and epithelial dysfunctions.
NovoMedix’s technology platform consists of a library of oral small molecule IL-11 inhibitors with compelling data in animal models of cancer and fibrosis coupled with remarkable safety profiles. The company’s leading pre-clinical therapeutic candidates are NMX1 in oncology and NMX2 in fibrosis. In in vitro and in vivo animal models, NMX1 arrests tumor growth, prevents metastasis, and is synergistic with chemotherapy and checkpoint inhibitors. NMX2 has reversed lung/liver fibrosis in pre-clinical models, and also exhibits synergies with two of the leading anti-fibrotic drugs available today. Intriguingly, both of these first in class inhibitors have unique cardio-protective properties that protect the heart from inflammation, fibrosis, and cardiac failure in multiple disease animal models.
November 5, 2021
NovoMedix will participate in the upcoming Life Sciences Summit (LSS) on November 9-10, 2021. LSS is an early stage investor and business development conference that highlights innovation that connects emerging biotech companies and academic innovators with the capital and strategic partners they will need to move new discoveries through clinical development. The conference features corporate presentations by promising young companies with transformative science that targets unmet medical needs.
September 1, 2021
NovoMedix is the recipient of an Phase I SBIR Grant funded by the National Heart, Lung, And Blood Institute of the National Institutes of Health (award Number 1R43HL160460) titled: Novel Therapy for Protection against Diabetes and its Complications in Ischemic Heart Disease.
October 20, 2020
The abstract titled "Novel Dual MTOR Inhibitor/AMPK Activator Mitigates Doxorubicin Cardiotoxicity And Potentiates Its Chemotherapeutic Efficacy Against Triple Negative Breast Cancer", has been accepted for virtual presentation (Abstract #17055) at Scientific Sessions 2020 November 13-17. For a copy of the poster, please email firstname.lastname@example.org
April 26, 2020
Late Breaking Research titled: "Synergistic anti-metastatic effect of pembrolizumab in combination with a novel mTORC1 inhibitor/AMPK agonist in a CAM metastatic triple negative breast cancer model" to be presented as an E-Poster (Tumor Biology 2, Abstract# 10226) at the Virtual AACR 2020 Annual Meeting. For a copy of the poster, please email email@example.com